Sicor’s Prostate Cancer Drug Approved

Sicor Inc., an Irvine specialty pharmaceutical company, said Friday that its Gensia Sicor Pharmaceuticals Inc. unit received Food and Drug Administration approval of its new leuprolide injection drug. Leuprolide is used to lessen the severity of advanced prostate cancer. Sicor said in a news release that Gensia Sicor’s leuprolide product will be available in a shatter-resistant polymer plastic vial, which the company said should be a significant advantage over currently available products in glass vials for those who self-administer the drug.